Skip to content
Search
Please enter at least 3 characters.

Latest Stories

Assisted Dying: RPS Scotland supports pharmacists' right to opt-out of the process

Assisted Dying: RPS Scotland supports pharmacists' right to opt-out of the process

RPS says that the ability of pharmacists to conscientiously object to Assisted Dying is essential

The Royal Pharmaceutical Society (RPS) has taken a neutral stance on the Assisted Dying for Terminally Ill Adults (Scotland) Bill but underscores that pharmacists should have the right to refuse involvement in the process.


The Bill, introduced to the Scottish Parliament by Liam McArthur MSP as a Private Members Bill, could make Scotland the first UK nation with assisted dying legislation if it passes into law.

This week, the RPS in Scotland released its consultation response to the Scottish Parliament’s Health, Social Care, and Sport Committee regarding the Bill, and made it clear that “the ability of pharmacists to conscientiously object to assisted dying is essential.”

The Society emphasised that “all pharmacists should have the right to take part, or not take part in the process, depending on their individual religious, moral or ethical beliefs.”

In its response, the RPS has also advocated for the inclusion of an opt-in section within the Bill.

“Pharmacists should only be taking part in this process, whether directly or indirectly, where they are comfortable to do so,” it said, noting that “this would not only support individual healthcare professionals but would also ensure the best patient care and experience.”

Furthermore, the RPS has called for greater clarity in the proposed role of the pharmacist in the assisted dying process.

“In the Bill as drafted, a pharmacist may be present in some circumstances but not in others.  There should be clarity and consistency throughout the process,” the Society noted.

As the draft Bill progresses through scrutiny by the Health, Social Care and Sport Committee and the legislative process, the RPS Scotland plans to continue presenting its views to MSPs and stakeholders throughout the country.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less